Active rh FLt3 – RF0039, RF0040, RF0041

  • Product under demand. Please contact us directly at: info@agrenvec.es
  • Description: Active human FLt3
  • Application: BIOASSAY, SDS-PAGE, WB
  • Alternative Names: SL cytokine
  • UniProtKB: P49771-1
Download datasheet

Description

Molecular weight: Recombinant human FLt3 is a polypeptide chain containing 165 amino acids (27–181 of P49771-1 FLT3L_HUMAN). It has a predicted molecular mass of 18.4 kDa, however as result of potential glycosylation, the recombinant protein could migrate with an apparent molecular mass of 18-25 kDa in SDS-PAGE.

Description: FLt3 ligand is a transmembrane glycoprotein that activates the FLt3 receptor (CD135, FLK2). FLT3 ligand, in synergy with other cytokines, stimulates the growth and differentiation of a number of important cell populations. Activation of FLt3 stimulates the growth and differentiation of very early stem cells involved in hematopoiesis, myelopoiesis, erythropoiesis and megakaryopoiesis. FLt3 activation mobilizes hematopoietic progenitor cells into peripheral blood and induces proliferation of myeloid and dendritic cells (DC). Dysregulation of FLt3 has been associated with acute leukemia(s) involving myeloid (AML), T, and B blast cell(s).

RF0039-SDS-PAGE-y-WB-FLT3-NEW-205x300
Figure 1.SDS-PAGE and Western blot analysis of human recombinant FLt-3. Lane MWM: molecular weight marker (kDa). Lane1: coomassie blue 0,3 µg of recombinant FLt-3 and lane 2: 0,3 µg of recombinant FLt-3. All the bands shown in lanes 1-2 have been identify by MALDI-TOFF as recombinant FLt3.

RF0039-40-41-Biological-Activity-FLT3L-WEB-980x197

Biological Activity: The activity of Flt-3is determinated by the dose-dependent stimulation of the proliferation of human acute myeloid leukemia cells (OCMI-AML5). ED50 is typically  ≤ 1 ng/ml.

Human recombinant protein expressed in Nicotiana.

Bulk sizes are available upon request.

For R&D purposes only. Purchaser must determine the suitability of the product(s) for their particular use.

Additional Information

Additional Information
Format PLEASE INQUIRE